63329-53-3

Usage

Uses

Used in Antirheumatic Applications:
Lobenzarit is used as an antirheumatic agent for the treatment of arthritis. It helps to reduce inflammation, pain, and swelling in the joints, improving the overall quality of life for patients suffering from this condition.
Used in Immunomodulation:
Lobenzarit is used as an immunomodulator to regulate the immune system's response in various autoimmune and inflammatory disorders. Its immunosuppressive properties help to alleviate symptoms and prevent further damage to the affected tissues.
Used in Pharmaceutical Industry:
Lobenzarit is used as a drug for the treatment of rheumatoid arthritis and other inflammatory conditions. Its chemical scaffold has also been repurposed to target tryptophan biosynthesis in Mycobacterium tuberculosis, indicating its potential for further therapeutic applications in the pharmaceutical industry.

InChI:InChI=1/C14H10ClNO4/c15-8-5-6-10(14(19)20)12(7-8)16-11-4-2-1-3-9(11)13(17)18/h1-7,16H,(H,17,18)(H,19,20)

Upstream product

• 50-84-0 2,4 dichlorobenzoic acid 
• 118-92-3 anthranilic acid 
• 123-51-3 i-Amyl alcohol 
• 7440-44-0 pyrographite 
• 89-77-0 2-Amino-4-chlorobenzoic acid 

Downstream Products

• 1422064-45-6 4-chloro-N'-(4-methoxybenzylidene)-2-{2-[2-(4-methoxybenzylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-44-5 4-chloro-N'-(4-hydroxy-3,5-dimethylbenzylidene)-2-{2-[2(4-hydroxy-3,5-dimethylbenzylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-43-4 4-chloro-N'-(4-hydroxybenzylidene)-2-{2-[2(4-hydroxybenzylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-42-3 4-chloro-N'-(4-chlorobenzylidene)-2-{2-[2-(4-chlorobenzylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-41-2 4-chloro-2-[2-(hydrazinecarbonyl)phenylamino]benzohydrazide 
• 1422064-59-2 2-{4-chloro-2-[2-(2-(phenylcarbamothioyl)hydrazinecarbonyl)phenylamino]benzoyl}-N-phenylhydrazinecarbothioamide 
• 1422064-58-1 2-{4-chloro-2-[2-(2-(cyclohexylcarbamothioyl)hydrazinecarbonyl)phenylamino]benzoyl}-N-cyclohexylhydrazinecarbothioamide 
• 1422064-57-0 2-{4-chloro-2-[2-(2-(ethylcarbamothioyl)hydrazinecarbonyl)phenylamino]benzoyl}-N-ethylhydrazinecarbthioamide 
• 1422064-56-9 4-chloro-N'-[1-(4-hydroxyphenyl)propylidene]-2-{2-[2-(1-(4-hydroxyphenyl)propylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-55-8 4-chloro-N'-(1-phenylpropylidene)-2-{2-[2-(1-phenylpropylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-54-7 4-chloro-N'-(1-p-tolylethylidene)-2-{2-[2-(1-p-tolylethylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-53-6 4-chloro-N'-[1-(4-methoxyphenyl)ethylidene]-2-{2-[2-(1-(4-methoxyphenyl)ethylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-52-5 4-chloro-N'-[1-(4-hydroxyphenyl)ethylidene]-2-{2-[2-(1-(4-hydroxyphenyl)ethylidene)hydrazinecarbonyl]phenylamino}benzohydrazide 
• 1422064-51-4 N'-[1-(4-bromophenyl)ethylidene]-2-{2-[2-(1-(4-bromophenyl)ethylidene)hydrazinecarbonyl]phenylamino}-4-chlorobenzohydrazide 

Relevant academic research and scientific papers

Method for synthesizing N-o-carboxypnenyl-4-chloro-2-aminobenzoic acid serving as intermediate of lobenzarit medicine

A method for synthesizing N-o-carboxypnenyl-4-chloro-2-aminobenzoic acid serving as an intermediate of a lobenzarit medicines includes steps: (i) adding 400ml of diethyl ether, 0.079mol of 2-amino-4-chlorod-benzoic acid (2), 0.016-0.018mol of o-aminobenzoic acid (3), 0.19-0.21mol of ethylenediamine and 3.8g of nickel powder into a reaction vessel with a stirrer, a temperature gauge and a dropping funnel, controlling a stirring speed to be 180-210rpm, enabling a reflux reaction to last for 8-9h, leaching, dissolving a filter cake into 500ml of a salt solution, performing molecular sieve decoloration, adding an oxalic acid solution, keeping a pH value of the solution at 5-6, precipitating solids, filtering, washing with a potassium chloride solution, and recrystallizing in methylamine to obtain light yellow solid N-o-carboxypnenyl-4-chloro-2-aminobenzoic acid. The diethyl ether refers to absolute diethyl ether, and the salt solution refers to either a copper sulfate solution or a ferric nitrate solution.

A nitrogen hetero-cycloalkyl amino quinacridineone-4-amide compound and its preparation method and application

The invention provides an azo-heteroaromatic cycloalkylaminoacridone-4-amide compound which is shown in a formula I or a formula II as shown in the specification, as well as a preparation method and application thereof. In the formula I and the formula II

Molecular design, synthesis and biological research of novel pyridyl acridones as potent DNA-binding and apoptosis-inducing agents

A series of novel pyridyl acridone derivatives comprised of a pseudo-five-cyclic system to extend the π-conjugated acridone chromophore, were designed and synthesized as potent DNA binding antitumor compounds. Most synthesized compounds displayed good act

Design, synthesis and anti-inflammatory activity of structurally simple anthranilic acid congeners devoid of ulcerogenic side effects

Simple, three classes of new anthranilic acid derivatives were aimed at, synthesized and tested for their toxicity, anti-inflammatory, analgesic, antipyretic activity. Also, their potential protective role against ulcerative colitis in rats was performed.

Potential antitumor agents. 38. 3-Substituted 5-carboxamido derivatives of amsacrine

The synthesis and biological evaluation of a series of 3-substituted 5-carboxamido derivatives of amsacrine (m-AMSA) are described. This series was developed as the result of previous quantitative structure-activity relationship (QSAR) studies of the antitumor activity of 9-anilinoacridine derivatives. In agreement with these studies, this class of compounds, possessing a variety of small nonpolar groups at the 3-position, together with very hydrophilic carboxamido groups at the 5-position, have high in vivo activity against animal leukemia models.

Novel aminobenzoic acid derivatives, process for preparing the same and pharmaceutical composition containing the same

An aminobenzoic acid derivative represented by the formula STR1 wherein R1, R2 and R3 are defined hereinbelow, which has excellent activity for improving liver function and for potentiating and normalizing immunity; a process for preparing the same; and a pharmaceutical composition containing the same are disclosed.